Clinical Research Directory
Browse clinical research sites, groups, and studies.
Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF]
Sponsor: AstraZeneca
Summary
The CHRONICLES study will investigate the change in clinical and patient reported outcomes after six-months of treatment with Budenoside/Glycopyrronium/Formoterol \[BGF\] in a real-world setting.
Official title: Chronicling the COPD Patient Journey and Change in Impact of a Single Inhaler Combination Therapy on COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF](CHRONICLES COPD)
Key Details
Gender
All
Age Range
35 Years - 130 Years
Study Type
OBSERVATIONAL
Enrollment
152
Start Date
2024-09-17
Completion Date
2026-05-20
Last Updated
2026-02-04
Healthy Volunteers
No
Interventions
Budenoside/Glycopyrronium/Formoterol
Patients with COPD who initiate BGF as prescribed by physician per the approved country-specific label and reimbursement criteria
Locations (1)
Research Site
Windsor, Ontario, Canada